# INCB161734-101 (INCB161734): what clinicians are saying

> 32 statements from 18 sources (3 videos, 15 posts), 16 of them from 9 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026.

## Report

- Trial: A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT ID: NCT06179160
- Registry: https://clinicaltrials.gov/study/NCT06179160
- Sponsor: Incyte Corporation
- Phase: Phase 1
- Status: Recruiting
- Drugs tested: INCB161734; INCB161734 plus cetuximab; INCB161734 plus retifanlimab
- Indication: KRAS G12D-mutated advanced or metastatic solid tumors
- Version: v1.0.0, edition 1
- Accepted: 2026-11-20 UTC
- Last checked: 2026-11-20 UTC
- Release hash: 7e2ce92164533c68626f4bf382b671ec14e6b84af323b4cf4d5a6ff9f8b10512

## Counts

- Commentary sources screened: 28
- Sources cited by verified statements: 18
- Verified statements: 32
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 16
- Findings: 6
- Named people in screened sources (unnamed speakers and accounts not counted): 16
- Speakers cited: 16
- Cited speakers with a verified identity: 13
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 9
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 9
- By role and specialty (the abstract's specialty counts):
  - 7 physician, Medical oncology
  - 1 physician, specialty not confirmed
  - 1 physician, Gastroenterology
- Organisational or shared accounts (not counted as people): 1

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

For INCB161734-101, a speaker described in the sources as presenting the trial favors cetuximab-combination development in CRC given limited single-agent activity, without randomized proof of benefit. Medical oncologists consider chemotherapy combinations feasible in PDAC; a speaker tentatively favors FFXN for potentially lower GI toxicity. Durability remains uncertain. The sources place INCB161734 phase 1 PDAC findings at ASCO GI 2026, with updated PDAC combination results at ESMO 2026.

## Question clinicians left open

What do clinicians need to see on activity and tolerability from larger INCB161734–cetuximab cohorts and chemotherapy combinations to build on phase 1b findings in heavily pretreated KRAS G12D-mutant metastatic colorectal cancer?

From findings F1 (9 statements from 3 speakers in 3 sources) and F5 (7 statements from 6 speakers in 6 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. CRC: speakers note cetuximab combo activity; most see combos as needed
  - 9 statements from 3 speakers in 3 sources, all podcasts or videos.
  - 3 of the 3 named speakers in this finding hold this view; 2 of them hold its caveat, “most see combos as needed”.
  - No named clinician · accounts and unnamed speakers.
- F2. PDAC phase 1 combos: some clinicians see feasibility; a speaker weighs GI trade-offs
  - 10 statements from 8 speakers in 9 sources.
  - 4 of the 8 named speakers in this finding hold this view, each a confirmed clinician; 1 of the 8 holds its caveat, “a speaker weighs GI trade-offs”.
  - 6 of the report's 9 cited clinicians.
- F3. PDAC phase 1: most speakers highlight responses; a clinician awaits PFS/OS medians
  - 13 statements from 7 speakers in 8 sources.
  - 6 of the 7 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician awaits PFS/OS medians”.
  - 5 of the report's 9 cited clinicians.
- F4. KRAS trial choice: a speaker asks why QTX3034 was chosen over other KRAS trials
  - 2 statements from 1 speaker in 2 sources.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.
- F5. KRAS: most speakers welcome development; a clinician expects a PDAC standard of care
  - 7 statements from 6 speakers in 6 sources.
  - 5 of the 6 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician expects a PDAC standard of care”.
  - 5 of the report's 9 cited clinicians.
- F6. Appendix cancer: a clinician proposes a trial, ideally with a PD1 inhibitor
  - 1 statement from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “ideally with a PD1 inhibitor”.
  - 1 of the report's 9 cited clinicians.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 9 | 4 | 3 | 3 | 4 |
| F2 | 10 | 9 | 9 | 8 | 4 |
| F3 | 13 | 8 | 8 | 7 | 5 |
| F4 | 2 | 2 | 2 | 1 | 3 |
| F5 | 7 | 6 | 6 | 6 | 3 |
| F6 | 1 | 1 | 1 | 1 | 1 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 6 | 0 | 0 | 2 | 1 | 10 | 1 | 3 podcasts and video |
| F2 | 6 | 0 | 0 | 1 | 3 | 10 | 0 | 9 posts and articles |
| F3 | 7 | 2 | 0 | 0 | 4 | 13 | 0 | 8 posts and articles |
| F4 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 2 posts and articles |
| F5 | 7 | 0 | 0 | 0 | 0 | 7 | 0 | 6 posts and articles |
| F6 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 post or article |

### Trial dimensions

- Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs): F2 (1 shared claims), F3 (1 shared claims)
- Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs): F1 (1 shared claims), F2 (2 shared claims), F3 (1 shared claims)
- Primary endpoint: Number of participants with TEAEs leading to dose modification or discontinuation: F1 (1 shared claims), F2 (1 shared claims), F3 (1 shared claims)
- Secondary endpoint: INCB161734 pharmacokinetic (PK) in Plasma: no finding draws on it directly
- Secondary endpoint: Objective Response Rate (ORR): F1 (4 shared claims), F2 (6 shared claims), F3 (4 shared claims), F5 (1 shared claims)
- Secondary endpoint: Disease Control Response (DCR): F1 (1 shared claims), F2 (2 shared claims), F5 (1 shared claims)
- Secondary endpoint: Duration of Response (DOR): F3 (1 shared claims), F5 (1 shared claims)
- Population and setting: F1 (3 shared claims), F2 (1 shared claims), F3 (2 shared claims)
- The comparison: F1 (4 shared claims), F2 (3 shared claims), F3 (2 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (7 shared claims), F3 (3 shared claims), F5 (2 shared claims)
- Design and conduct: F1 (3 shared claims), F2 (1 shared claims), F3 (1 shared claims)

## Abbreviations

- ASCO: American Society of Clinical Oncology
- CRC: colorectal cancer
- DCR: disease control rate
- DLT: dose-limiting toxicity
- DOR: duration of response
- ESMO: European Society for Medical Oncology
- GI: gastrointestinal
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- ORR: objective response rate
- OS: overall survival
- PDAC: pancreatic ductal adenocarcinoma
- PFS: progression-free survival
- SAE: serious adverse event

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 32 | Paid |
| Who said each statement: the cited speakers | 16 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 9 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 13 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 16 | Free |
| Sources with links | 18 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 9 of the 16 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

15 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs) | discussed | 1 | 1 |
| Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs) | discussed | 3 | 3 |
| Primary endpoint: Number of participants with TEAEs leading to dose modification or discontinuation | discussed | 2 | 2 |
| Secondary endpoint: INCB161734 pharmacokinetic (PK) in Plasma | no commentary found | 0 | 0 |
| Secondary endpoint: Objective Response Rate (ORR) | discussed | 12 | 10 |
| Secondary endpoint: Disease Control Response (DCR) | discussed | 3 | 3 |
| Secondary endpoint: Duration of Response (DOR) | discussed | 1 | 1 |
| Population and setting | discussed | 6 | 6 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 8 | 7 |
| Safety and tolerability | discussed | 8 | 8 |
| Design and conduct | discussed | 5 | 4 |
| ctDNA response and possible KRAS copy-number resistance | discussed | 5 | 3 |
| Survival follow-up and six-month PFS reporting | discussed | 2 | 2 |
| Trial visibility and choice among KRAS studies | discussed | 2 | 2 |
| Forward-looking PDAC positioning and development expectations | discussed | 7 | 6 |
| Proposed appendix-cancer study with PD1 blockade | discussed | 1 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 9 statements · 28%** | | | |
| YouTube | 9 | 3 | 3 |
| **Posts · 23 statements · 72%** | | | |
| X threads | 23 | 15 | 24 |
| Bluesky threads | 0 | 0 | 1 |

- Screened window: 2023-12-21 to 2026-11-02
- Cited window: 2023-12-21 to 2026-11-02
- Retrieved: 2026-11-20

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Registry: NCT06179160 (https://clinicaltrials.gov/study/NCT06179160)
- Study IDs: INCB161734-101 · 2023-507091-47-00 (EU CT Number)
- Sponsor: Incyte Corporation
- Design: Phase 1 · interventional, non randomized, sequential, phase1
- Status: Recruiting
- Enrollment: 710 (estimated)
- Start: 2024-01-04 (actual)
- Primary completion: 2027-01-01 (estimated)
- Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs) (Up to 28 days)
- Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs) (Up to 2 years and 90 days)
- Primary endpoint: Number of participants with TEAEs leading to dose modification or discontinuation (Up to 2 years and 90 days)
- Intervention: INCB161734 (drug)
- Intervention: Cetuximab (drug)
- Intervention: Retifanlimab (drug)
- Intervention: GEMNabP (drug)
- Intervention: mFOLFIRINOX (drug)
- Intervention: FOLFOX (drug)
- Intervention: FOLFIRI (drug)
- Intervention: INCA33890 (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on an alternative treatment considered during KRAS-targeted trial selection.
- 14 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 17 sources about other trials or topics are not included.
- The sources reviewed for this edition do not represent all HCPs or all public discussion. Reposts and quoted redistribution do not establish independent endorsement.
- Most cited remarks describe phase 1 INCB161734 or KRAS G12D inhibitor experience in PDAC or CRC without naming NCT06179160. They are treated as contextual commentary on its clinical question, not automatically reassigned as outcomes documented for that registry number.
- Search coverage may miss unnamed trial references or transcription variants, so an issue absent from this report may still have been discussed elsewhere.
- No publication specific to NCT06179160 was identified, no protocol was listed in ClinicalTrials.gov, and no exact INCB161734 label was identified. Some related regulatory material was not assessed; this does not establish approval status.
- Small early cohorts, different pretreatment histories, doses, efficacy denominators and reporting timepoints prevent pooling or conclusions about comparative treatment effects.
- A speaker's use of SAEs for mostly grade 1/2 events, unclear allocation of percentages to cohorts, and qualitative safety descriptions elsewhere limit standardized interpretation of tolerability.
- The statements do not establish mature durability, a validated survival-surrogate role for ctDNA response, or a causal KRAS copy-number resistance mechanism.
- Development forecasts, first-line positioning, best-in-class language and the appendix-cancer proposal are opinions or proposed research directions, not established treatment benefits.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-20 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-20 UTC. No changes.

## Offer

- Size: Focused · 32 verified statements · 16 from 9 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (13 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/incb161734-101-nct06179160
- Agents: POST https://www.erudio.com/api/orders with {"report": "incb161734-101-nct06179160", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=incb161734-101-nct06179160

## Cite

Erudio Health. INCB161734-101 (NCT06179160): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/incb161734-101-nct06179160

## Questions

### How much does the INCB161734-101 report cost?

One edition costs $750 (Focused · 32 verified statements · 16 from 9 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the INCB161734-101 report cover?

32 statements from 18 sources (3 videos, 15 posts), 16 of them from 9 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the INCB161734-101 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "incb161734-101-nct06179160" }) previews it and create_order({ "report": "incb161734-101-nct06179160", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the INCB161734-101 report?

Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/incb161734-101-nct06179160.json
- Markdown: https://www.erudio.com/reports/incb161734-101-nct06179160.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/incb161734-101-nct06179160/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "incb161734-101-nct06179160"}`
